(R)-1-[3,5-Bis(trifluoromethyl)phenyl]ethanol
CAS: 127852-28-2
Ref. TR-B416125
5g | 118,00 € | ||
25g | 445,00 € | ||
100g | 1.239,00 € |
Información del producto
- (alphaR)-alpha-methyl-3,5-bis(trifluoromethyl)-Benzenemethanol
- (1R)-1-[3,5-Bis(Trifluoromethyl)phenyl]ethanol
- (1R)-1-[3,5-Bis(trifluoromethyl)phenyl]ethan-1-ol
- (1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethanol
- (R)-1-(3,5-Bis(Trifluoromethyl)Phenyl)Ethan-1-Ol
- (R)-1-(3,5-Bis-trifluoromethylphenyl)ethanol
- (R)-1-3,5-Bis(trifluoromethyl) phenylethanol
- (R)-1-[3,5-Bis(Trifluoro-Methyl)-Phenyl]Ethanol
- (R)-1-[Bis-3,5-(Trifluoromethyl)Phenyl]Ethanol
- (R)-[3,5-Bis(trifluoromethyl)phenyl]ethanol
- Ver más sinónimos
- (R)-bis-3,5-trifluoromethyl-1-phenylethanol
- (αR)-α-Methyl-3,5-bis(trifluoromethyl)benzenemethanol
- 1-[3,5-Bis(Trifluoromethyl)Phenyl]Ethanol
- 1R)-1-[3,6-Bis(Trifluoromethyl)Phenyl]Ethanol
- Aprepitant Intermediate
- Benzenemethanol, A-Methyl-3,5-Bis(Trifluoromethyl)-, (Ar)-
- Benzenemethanol,a-methyl-3,5-bis(trifluoromethyl)-,(R)-
- R-Mbt-Pel
Applications (R)-1-[3,5-Bis(trifluoromethyl)phenyl]ethanol is an intermediate in the synthesis of Aprepitant (A729800), a novel selective neurokinin-1 (NK-1) receptor antagonist. In vitro studies using human liver microsomes indicate that Aprepitant is metabolised primarily by CYP3A4 with minor metabolism by CYP1A2 and CYP2C19, and no metabolism by CYP2D6, CYP2C9, or CYP2E1. Antiemetic.
References Vankawala, P.J., et. al.: Synthetic Comm., 37, 3439 (2007); Hale, J.J., et al.: J. Med. Chem., 41, 4607 (1998); Campos, D., et al.: J. Clin. Oncol., 19, 1759 (2001); Van Belle, S., et al.: Cancer, 94, 3032 (2002); Majumdar, A.K., et al.: J. Clin. Pharmacol., 46, 291 (2006)
Propiedades químicas
Consulta técnica sobre: TR-B416125 (R)-1-[3,5-Bis(trifluoromethyl)phenyl]ethanol
Si desea solicitar un presupuesto o realizar un pedido, por favor añada los productos deseados a su carrito y solicite un presupuesto o pedido desde el carrito. Es más rápido, más barato, y podrá beneficiarse de los descuentos y las ventajas disponibles.